This activity is supported by educational grants from Abbott, AstraZeneca, Bayer, Chiesi, NovoNordisk.
In case you missed the tweetorial on Twitter “real time” you can review the course material here and earn the same credit.
2) First, a poll: SGLT-2 inhibitors were first approved by FDA to reduce the risk of hospitalization for HF in both diabetics and nondiabetics?— cardio-met (@cardiomet_CE) January 28, 2021
4) Welcome back to our accredited tweetorial! SGLT-2i were approved to reduce the risk of hosp for HF in both diabetics and nondiabetics in 2020. We’ll now review some slides. #ruralhealth #Cardiology #CME— cardio-met (@cardiomet_CE) January 29, 2021
<blockquote class=”twitter-tweet”><p lang=”und” dir=”ltr”>6) <a href=”https://t.co/kzaIaKguHL”>pic.twitter.com/kzaIaKguHL</a></p>— cardio-met (@cardiomet_CE) <a href=”https://twitter.com/cardiomet_CE/status/1355105216602009601?ref_src=twsrc%5Etfw”>January 29, 2021</a></blockquote> <script async src=”https://platform.twitter.com/widgets.js” charset=”utf-8″></script>
20) Welcome back to our accredited tweetorial! Here are the 2021 ADA Guidelines for T2D management in pts at risk for poor cardiorenal/CV outcomes. You’ll see more here about the optimal use of SGLT2i and other agents. #cardiotwitter #MedTwitter #tweetorial @drricardocorrea— cardio-met (@cardiomet_CE) January 30, 2021
24) How to choose between them? Bailey in 2020 Lancet-Diab-Endo writes that safety concerns, cost, and the preferences of individual clinicians and patients will drive decisionmaking. Clinician prefs are likely to take account of local guidelines, previous experiences . . .— cardio-met (@cardiomet_CE) January 30, 2021
26) In cases where renal parameters were tracked in CVOTs GLP-1 RAs and SGLT-2i reduced the onset and progression of microalbuminuria and macroalbuminuria. SGLT-2i reduce rate of decline in eGFR. Thus, the renal protection conferred by GLP-1 RAs is mainly associated with . . .— cardio-met (@cardiomet_CE) January 30, 2021
30) a final meta-analysis: pic.twitter.com/MUx8D4QLur— cardio-met (@cardiomet_CE) January 30, 2021
31) Now, here’s a case for you . . .— cardio-met (@cardiomet_CE) January 30, 2021
33) Which of the following meds will be the best one to add to his regimen?— cardio-met (@cardiomet_CE) January 30, 2021
35) The best new med for our patient would be dapagliflozin, given his renal status and HF. You made it! Free CE/CME! Now go to https://t.co/HhLqzyMqlV and claim your credit! I am @drricardocorrea. Follow @cardiomet_CE for more tweetorials! #cardiotwitter @academiccme— cardio-met (@cardiomet_CE) January 31, 2021